Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Endogenous Fungal Endophthalmitis Following Covid-19 Hospitalization: Evidence From a Year-Long Observational Study; [Endophtalmie Fongique Endogene Suite a Une Hospitalisation Pour Covid-19 : Preuves D'une Etude Observationnelle D'un An] Publisher Pubmed



Fekri S1, 2 ; Khorshidifar M1, 2 ; Esfahanian F3 ; Veisi A1 ; Nouri H1, 3, 4 ; Abtahi SH1, 5, 6
Authors

Source: Journal Francais d'Ophtalmologie Published:2023


Abstract

Purpose: To describe cases of endogenous fungal endophthalmitis (EFE) post-recovery from or hospitalization for coronavirus disease 2019 (COVID-19). Methods: This prospective audit involved patients with suspected endophthalmitis referred to a tertiary eye care center over a one-year period. Comprehensive ocular examinations, laboratory studies, and imaging were performed. Confirmed cases of EFE with a recent history of COVID-19 hospitalization ± intensive care unit admission were identified, documented, managed, followed up, and described. Results: Seven eyes of six patients were reported; 5/6 were male, and the mean age was 55. The mean duration of hospitalization for COVID-19 was approximately 28 days (14–45); the mean time from discharge to onset of visual symptoms was 22 days (0–35). All patients had underlying conditions (5/6 hypertension; 3/6 diabetes mellitus; 2/6 asthma) and had received dexamethasone and remdesivir during their COVID-related hospitalization. All presented with decreased vision, and 4/6 complained of floaters. Baseline visual acuity ranged from light perception (LP) to counting fingers (CF). The fundus was not visible in 3 out of 7 eyes; the other 4 had “creamy-white fluffy lesions” at the posterior pole as well as significant vitritis. Vitreous taps were positive for Candida species in six and Aspergillus species in one eye. Anti-fungal treatment included intravenous amphotericin B followed by oral voriconazole and intravitreal amphotericin B. Three eyes underwent vitrectomy; the systemic health of two patients precluded surgery. One patient (with aspergillosis) died; the others were followed for 7–10 months – the final visual outcome improved from CF to 20/200–20/50 in 4 eyes and worsened (hand motion to LP) or did not change (LP), in two others. Conclusion: Ophthalmologists should maintain a high index of clinical suspicion for EFE in cases with visual symptoms and a history of recent COVID-19 hospitalization and/or systemic corticosteroid use – even without other well-known risk factors. © 2023 Elsevier Masson SAS
Other Related Docs
6. Ocular Disorders in Renal Transplant Patients, Journal of Ophthalmic and Vision Research (2007)
11. Clinical Patterns of Uveitis in an Iranian Tertiary Eye-Care Center, Ocular Immunology and Inflammation (2015)
12. Autoimmune Retinopathy Following Covid-19: A Case Report, Ocular Immunology and Inflammation (2024)
13. A Rare Complication of Toxoplasmosis: Retinal Neovascularisation, American Journal of Case Reports (2008)
16. Acute Retinal Necrosis After Herpetic Encephalitis, Case Reports in Ophthalmology (2010)